LOGIN  |  REGISTER
C4 Therapeutics

Artivion to Present at the Deutsche Bank 31st Annual Leveraged Finance Conference

September 26, 2023 | Last Trade: US$26.73 0.32 1.21

ATLANTA, Sept. 26, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deutsche Bank 31st Annual Leveraged Finance Conference on Tuesday, October 3, 2023. The Company's presentation is scheduled to begin at 10:40 a.m. MST.

A live webcast of the presentation will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.

About Artivion, Inc.

Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.

Contacts:

  

Artivion

 

Gilmartin Group LLC

D. Ashley Lee

 

Brian Johnston / Lynn Lewis 

Executive Vice President &

 

Phone: 332-895-3222

Chief Financial Officer

 

This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: 770-419-3355

  
   
C4 Therapeutics

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB